1 Rackemann FM. A clinical study of one hundred and fifty cases of bronchial asthma. Arch Intern Med. 1918;2:517–22.
2 Rothe T. A century of «Intrinsic Asthma». A view on the development of phenotyping in asthma in the last 100 years. Allergo J 2018;27:215–19 .
3
www.asthmacontroltest.com (download 03.06.2019).
4 Haldar P, P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178:218–24.
5 Turner-Warwick M. On observing patterns of airway obstruction in chronic asthma. Br J Dis Chest. 1977;71:73–86 .
6 Kurup VP, Banerjee B, Hemmann S et al. Selected recombinant Aspergillus fumigatus allergens bind specifically to IgE in ABPA. Clin Exp Allergy 2000;30:988–93.
7 Churg A, et al. Formes frustes of Churg Strauss syndrome. Chest 1995;108:320–3.
8 Chung KF. Shedding light on corticosteroid-resistant type 2 high severe asthma. J Allergy Clin Immunol 2019;143:89–90.
9 ten Brinke A, Zwinderman AH, Sterk PJ, et al. Refractory eosinophilic airway inflammation in severe asthma. Am J Respir Crit Care Med 2004;170:601–5.
10 Manali M, Bulir DC, Radford K et al. Sputum auto-antibodies in patients with severe eosinophilic asthma. J Allergy Clin Immunol 2018;141:1269–79.
11 Peters MC, Kerr S, Dunican M et al. Refractory airway type 2 inflammation in a large subgroup of asthmatic patients treated with inhaled corticosteroids. J Allergy Clin Immunol 2019;143:104–13.
12 Zoeppritz Ulrich. Die Therapie des Asthma bronchiale. Inauguraldissertation an der Universität Tübingen. 1948, Seite 26.
13 Brutsche MH, Downs S, Schindler C, Gerbase MW et al. Bronchial hyperresponsiveness and the development of asthma and COPD in asymptomatic individuals: SAPALDIA cohort study. Thorax. 2006;61:671–7 .
14 Bafadhel M, Greening NJ, Harvey-Dunstan TC, Williams JE et al. Blood eosinophils and outcomes in severe hospitalized exacerbations of COPD. Chest 2016;150:320–8.
15 Brusselle G, Maes T, Bracke K. Eosinophils in the spotlight: eosinophilic airway inflammation in non-allergic asthma. Nature Med. 2013;19:977.
16 Miravitlles M, Alvarez-Gutierrez FJ, Calle M, Casanova C, Cosio BG, López-Viña A, et al. Algorithm for identification of Asthma COPD Overlap. Eur Respir J 2017;49. pii: 1700068.
doi:10.1183/13993003.00068–2017.
17 Bel EH, ten Brinke A. New anti-eosinophil drugs for asthma and COPD. Chest 2017;152:1276–82.
18 Pavord ID, Chanez P, Criner GJ et al. Mepolizumab for eosinophilic COPD. N Engl J Med. 2017;377:1613–29.
19 Watz H, Tetzlaff K, Wouters EF, Kirsten A et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. 2016;4:390–8.
20 Chapman KR, Hurst JR, Frent SM et SUNSET investigators. Long-term triple therapy de-escalation to Indacaterol/ Glycopyrronium in patients with COPD: A randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med. 2018;198: 329–3.
21 Magnussen H, Disse B, Rodriguez-Roisin R et and WISDOM investigators. Withdrawel of inhaled corticosteroids and exacerbations of COPD. N Engl J Med 2014;371:1285–1294.
22 Wedzicha JA, Banerji D, Chapman KR and FLAME investigators. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med 2016;374:2222–34.
23 Pascoe S, Barnes N, Brusselle G et al. Late Breaking Abstract - Blood eosinophil counts and treatment response in COPD: analyses of IMPACT. European Respiratory Journal2018 52:OA2127;
DOI:10.1183/13993003.congress-2018.OA2127.
24 Cates C. Inhaled corticosteroids in COPD: quantifying risks and benefits. Thorax 2013;68:499–500.